Synthetic Biologics

View the org chart displaying its 7 main executives

Most searched biographies at Synthetic Biologics

• Steven Shallcross, Chief Executive Officer, Chief Financial Office...
• Jeffrey Wolf, Director
• Jeffrey Kraws, Chairman of the Board

Create your alert
to follow the executive moves at Synthetic Biologics.

Synthetic Biologics has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Synthetic Biologics

• Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting | Theriva™ Biologics
• Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results | Theriva™ Biologics
• Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results | Theriva™ Biologics
• Theriva™ Biologics to Participate in the BIO-Europe Spring Conference | Theriva™ Biologics
• Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma | Theriva™ Biologics
• Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference | Theriva™ Biologics
• Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results | Theriva™ Biologics
• Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 | Theriva™ Biologics
• Theriva™ Biologics to Participate in the BIO-Europe Conference | Theriva™ Biologics
• Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer | Theriva™ Biologics
• View more press releases Close

Social media about Synthetic Biologics

• Synthetic Biologics on Wikipedia, Google News & Yahoo Finance
• Synthetic Biologics on LinkedIn, Twitter & YouTube

Contact by email its executives including John Monahan

Call Synthetic Biologics at +1 734...

View the org chart

Register to receive your alert

Report an error